8-K: Bio-Techne Reports Flat Revenue, Higher EPS in Q2 FY26

Bio-Techne Corporation announced flat revenue growth but increased GAAP and adjusted earnings per share for its second fiscal quarter ended December 31, 2025, alongside a quarterly cash dividend.

Summary

• Second quarter fiscal 2026 revenue was $295.9 million, showing flat reported and organic growth compared to the prior year.
• GAAP earnings per share (EPS) increased to $0.24 from $0.22 in the prior year.
• Adjusted EPS rose to $0.46 compared to $0.42 in the prior year.
• Adjusted operating margin improved by 100 basis points to 31.1%, driven by productivity and cost containment.
• The company declared a quarterly cash dividend of $0.08 per share, payable February 27, 2026, to shareholders of record on February 16, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a solid performance in a challenging market, with strong profitability improvements and strategic growth in key segments offsetting flat top-line revenue. The dividend declaration further reinforces financial stability.

Positives

• GAAP EPS increased to $0.24 from $0.22 year-over-year.
• Adjusted EPS increased to $0.46 from $0.42 year-over-year.
• Adjusted operating margin improved by 100 basis points to 31.1% due to productivity and cost containment initiatives.
• GAAP operating income increased 15% to $54.5 million from $47.4 million in the prior year.
• Strong commercial execution and improving end-markets drove growth in the China/APAC region for the third consecutive quarter.
• Achieved double-digit growth in the large pharma end market for the fourth consecutive quarter.
• Improved performance in biotech and continued stabilization among U.S. academic customers.
• Diagnostics and Spatial Biology segment operating margin significantly increased to 10.4% from 3.9% in the prior year, aided by the Exosome Diagnostics divestiture and profitability initiatives.
• A quarterly cash dividend of $0.08 per share was declared.

Negatives

• Total revenue and organic growth were flat compared to the prior year.
• Protein Sciences segment organic revenue decreased by 1%.
• Protein Sciences segment operating margin decreased to 39.3% from 41.2% due to unfavorable product mix.
• Diagnostics and Spatial Biology segment net sales decreased by 4% to $81.2 million from $84.1 million in the prior year.
• Unfavorable product mix partially offset favorable impacts on GAAP and adjusted operating margins.

Risks

• The effect of new branding and marketing initiatives.
• Challenges in the integration of new businesses and leadership.
• Risks associated with the introduction and acceptance of new products.
• Dependence on the funding and focus of research types by customers.
• Impact of increasing competition from other producers of biotechnology research products and related price competition.
• General economic conditions.
• Impact of currency exchange rate fluctuations.
• Costs and results of research and product development efforts by the company and its strategic partners.
• Customer site closures or supply chain issues.

Future Outlook

The company anticipates continued innovation, growth, and value creation for stakeholders, building on its durable and differentiated portfolio that serves high-growth, high-value applications and accelerates innovation in science and medicine. Management expects ongoing stabilization in the operating environment and continued momentum in key end markets like large pharma and Asia.

Management Comments

• "I am pleased with the Bio-Techne team's continued execution in a stabilizing operating environment." Kim Kelderman, President and CEO.
• "For the fourth consecutive quarter we delivered double-digit growth in our biggest end market, large pharma." Kim Kelderman, President and CEO.
• "That momentum, together with improving performance in biotech, continued stabilization among our U.S. academic customers, and ongoing growth in Asia, drove results that were largely in line with our expectations." Kim Kelderman, President and CEO.
• "In 2026, Bio-Techne proudly celebrates its 50th anniversary." Kim Kelderman, President and CEO.
• "Over the past five decades, we have built a durable, differentiated portfolio that serves high-growth, high-value applications and accelerates innovation in science and medicine." Kim Kelderman, President and CEO.
• "As we look ahead, our strong position enables us to drive continued innovation, growth, and value for all our stakeholders." Kim Kelderman, President and CEO.

Industry Context

StockSavvy.ai notes that Bio-Techne's performance reflects a broader trend of stabilization in the life sciences sector, particularly with improving conditions in biotech and academic research, while large pharma continues to be a robust growth driver. The strong performance in China/APAC aligns with the region's increasing importance in global scientific research and development, a trend many competitors are also leveraging.

Comparison to Industry Standards

• Bio-Techne's flat revenue growth, while not stellar, is positioned within a "stabilizing operating environment," suggesting that the broader industry may also be experiencing moderate growth or recovery rather than aggressive expansion.
• The 100 basis point increase in adjusted operating margin to 31.1% demonstrates strong operational efficiency and cost control, potentially outperforming some peers facing inflationary pressures or higher R&D costs.
• Double-digit growth in large pharma for the fourth consecutive quarter indicates a strong competitive position and effective strategy in a critical market segment, potentially outpacing general market growth rates for suppliers to this sector.
• The significant improvement in the Diagnostics and Spatial Biology segment's operating margin from 3.9% to 10.4% suggests successful integration of divestitures and profitability initiatives, which could set a benchmark for efficiency improvements in similar diagnostic and spatial biology companies.

Stakeholder Impact

• Shareholders: Benefit from increased GAAP and adjusted EPS, improved operating margins, and a declared quarterly cash dividend of $0.08 per share.
• Employees: Benefit from ongoing productivity and cost containment initiatives, which contribute to the company's financial health and stability.
• Customers: Benefit from continued innovation and a durable, differentiated portfolio of products and services.
• Investment Professionals: Provided with detailed financial results and management commentary to inform investment decisions.

Next Steps

• Bio-Techne will host an earnings conference call on February 4, 2026, at 8:00 a.m. CST.
• The Board of Directors will consider future cash dividends on a quarterly basis.
• The company plans to drive continued innovation, growth, and value for all stakeholders.

Key Dates

Recommendation

The company demonstrated strong operational efficiency and profitability growth (adjusted EPS up, adjusted operating margin up 100 bps) despite flat revenue, indicating effective cost management and a resilient business model in a 'stabilizing operating environment.' Growth in key segments like large pharma and China/APAC is positive. However, flat overall revenue and a slight organic decline in Protein Sciences suggest that significant top-line growth catalysts are not immediately apparent. The dividend declaration signals financial stability. Given the mixed signals of strong profitability but stagnant revenue, a 'hold' recommendation is appropriate for investors awaiting clearer signs of accelerated revenue growth.

Keywords

Bio-Techne, TECH, Earnings, Q2 2026, Financial Results, Biotechnology, Life Sciences, Diagnostics, Protein Sciences, Spatial Biology, Dividend, SEC Filing, 8-K